PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

Core Insights - PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through innovative therapeutics [4] - The company will present at the Lytham Partners Fall 2025 Virtual Investor Conference on September 30, 2025, and participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025 [1][2][3] Conference Participation - At the Lytham Partners conference, management will engage in a fireside chat with Craig-Hallum Senior Research Analyst, Chase Knickerbocker, at 4:15 p.m. ET and will be available for one-on-one virtual meetings [2] - During the ROTH Healthcare Opportunities Conference, management will also participate in one-on-one meetings, with interested investors encouraged to contact their ROTH representative [3] Company Overview - PolyPid's proprietary PLEX technology allows for controlled, prolonged-release of therapeutics, enabling precise drug delivery over several days to months [4] - The company is preparing for the New Drug Application (NDA) submission of its lead product candidate, D-PLEX₁₀₀, aimed at preventing abdominal colorectal surgical site infections, expected in early 2026 [4] - PolyPid has a diverse pipeline that includes innovative treatments in oncology, obesity, and diabetes [4]